Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Joanne Lysaght"'
Autor:
Eimear Mylod, Fiona O’Connell, Noel E. Donlon, Maria Davern, Caroline Marion, Christine Butler, John V. Reynolds, Joanne Lysaght, Melissa J. Conroy
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Oesophagogastric adenocarcinomas (OAC) are poor prognosis, obesity-associated cancers which may benefit from natural killer (NK) cell-based immunotherapies. Cellular immunotherapies encounter two key challenges to their success in OAC, namel
Externí odkaz:
https://doaj.org/article/893b5ecdb958437faa29914c40f247e8
Autor:
Adele E. Connor, Claire Hughes, Lea Schäfer, Lorraine McNally, Deirdre O’ Raw, Katayoun Bahramian, Bridget Carr, Ingrid Halligan Dunne, Joanne Lysaght, Sharon A. O’ Toole, Jeremy C. Simpson, Antoinette S. Perry
Publikováno v:
Research Involvement and Engagement, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Public and Patient Involvement in research is becoming a requirement on most research funding applications; this includes both healthcare and lab-based research. Whilst case studies and practical guides have been developed and are well docum
Externí odkaz:
https://doaj.org/article/e41fb5ae0ff2409bb507e1ae1ff3a10c
Autor:
Maria Davern, Cillian O’ Donovan, Noel E. Donlon, Eimear Mylod, Caoimhe Gaughan, Anshul Bhardwaj, Andrew D. Sheppard, Dara Bracken-Clarke, Christine Butler, Narayanasamy Ravi, Claire L. Donohoe, John V. Reynolds, Joanne Lysaght, Melissa J. Conroy
Publikováno v:
Biomedicines, Vol 12, Iss 4, p 819 (2024)
The presence of an immunosuppressive tumour microenvironment in oesophageal adenocarcinoma (OAC) is a major contributor to poor responses. Novel treatment strategies are required to supplement current regimens and improve patient survival. This study
Externí odkaz:
https://doaj.org/article/3ca4eb6b6a0845a7a2adb872372af596
Autor:
Maria Davern, Caoimhe Gaughan, Fiona O’ Connell, Brendan Moran, Eimear Mylod, Andrew D. Sheppard, Sinead Ramjit, Jasmine Yun-Tong Kung, James J. Phelan, Matthew G. Davey, Eanna J. Ryan, Christine Butler, Laura Quinn, Claudine Howard, Emily Tone, Eimear Phoenix, Waqas T. Butt, Niamh Lynam-Lennon, Stephen G. Maher, Narayanasamy Ravi, Claire L. Donohoe, John V. Reynolds, Joanne Lysaght, Noel E. Donlon
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThis timely study assesses the immunosuppressive effects of surgery on cytotoxic Th1-like immunity and investigates if immune checkpoint blockade (ICB) can boost Th1-like immunity in the perioperative window in upper gastrointestinal canc
Externí odkaz:
https://doaj.org/article/e9a76b77fe4448bca0dc1485f4477ae2
Autor:
Maria Davern, Rebecca M. O’ Brien, Jason McGrath, Noel E. Donlon, Ashanty M. Melo, Croí E. Buckley, Andrew D. Sheppard, John V. Reynolds, Niamh Lynam-Lennon, Stephen G. Maher, Joanne Lysaght
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-19 (2022)
Abstract Chemotherapy upregulates immune checkpoint (IC) expression on the surface of tumour cells and IC-intrinsic signalling confers a survival advantage against chemotherapy in several cancer-types including oesophageal adenocarcinoma (OAC). Howev
Externí odkaz:
https://doaj.org/article/dc1658cc2c1c4f7893802d0bf5e392a0
Autor:
Maria Davern, Noel E. Donlon, Fiona O’ Connell, Andrew D. Sheppard, Conall Hayes, Ross King, Hugo Temperley, Christine Butler, Anshul Bhardwaj, Jenny Moore, Dara Bracken-Clarke, Claire Donohoe, Narayanasamy Ravi, John V. Reynolds, Stephen G. Maher, Melissa J. Conroy, Joanne Lysaght
Publikováno v:
Translational Oncology, Vol 20, Iss , Pp 101406- (2022)
Response rates to immune checkpoint blockade (ICB) remain low in oesophageal adenocarcinoma (OAC). Combining ICB with immunostimulatory chemotherapies to boost response rates is an attractive approach for converting ‘cold’ tumours into ‘hot’
Externí odkaz:
https://doaj.org/article/c52c824c793a4acdab0d58f23a41159d
Autor:
Maria Davern, Marie-Claire Fitzgerald, Croí E. Buckley, Aisling B. Heeran, Noel E. Donlon, Jason McGrath, Fiona O’ Connell, Malvika R. Deshpande, Conall Hayes, Jamie MacDonald, Andrew D. Sheppard, John V. Reynolds, Stephen G. Maher, Niamh Lynam-Lennon, Brona Murphy, Joanne Lysaght
Publikováno v:
Translational Oncology, Vol 19, Iss , Pp 101381- (2022)
Recent studies have demontrated that immune checkpoint receptors are expressed on the surface of oesophageal adenocarcinoma (OAC) cells and might confer a survival advantage. This study explores the role of PD-1 and TIGIT signalling in OAC cells in e
Externí odkaz:
https://doaj.org/article/96e5d6a96b624381831b60e85caffe2c
Autor:
Amy M. Buckley, Margaret R. Dunne, Maria E. Morrissey, Susan A. Kennedy, Aoife Nolan, Maria Davern, Emma K. Foley, Niamh Clarke, Joanne Lysaght, Narayanasamy Ravi, Dermot O’Toole, Finbar MacCarthy, John V. Reynolds, Breandán N. Kennedy, Jacintha O’Sullivan
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Abstract Oesophageal cancer is the 6th most common cause of cancer related death worldwide. The current standard of care for oesophageal adenocarcinoma (OAC) focuses on neoadjuvant therapy with chemoradiation or chemotherapy, however the 5-year survi
Externí odkaz:
https://doaj.org/article/e0a0a6fa4475406c8c5b27eb5adbbaa8
Autor:
Maria E. Morrissey, Róisín Byrne, Celina Nulty, Niamh H. McCabe, Niamh Lynam-Lennon, Clare T. Butler, Susan Kennedy, Dermot O’Toole, John Larkin, Paul McCormick, Brian Mehigan, Mary-Clare Cathcart, Joanne Lysaght, John V. Reynolds, Elizabeth J. Ryan, Margaret R. Dunne, Jacintha O’Sullivan
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Only 10–30% of oesophageal and rectal adenocarcinoma patients treated with neoadjuvant chemoradiotherapy have a complete pathological response. Inflammatory and angiogenic mediators in the tumour microenvironment (TME) may enabl
Externí odkaz:
https://doaj.org/article/eac61d4bd7544b4db891309c642d064c
Autor:
Noel E. Donlon, Maria Davern, Andrew D. Sheppard, Fiona O’Connell, Margaret R. Dunne, Conall Hayes, Eimear Mylod, Sinead Ramjit, Hugo Temperley, Michael Mac Lean, Gillian Cotter, Anshul Bhardwaj, Christine Butler, Melissa J. Conroy, Jacintha O’Sullivan, Narayanasamy Ravi, Claire L. Donohoe, John V. Reynolds, Joanne Lysaght
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundImmune checkpoint inhibitors (ICIs) are being investigated for their role as an adjunct in the multimodal treatment of esophageal adenocarcinoma (EAC). The most effective time to incorporate ICIs remains unknown. Our study profiles systemic
Externí odkaz:
https://doaj.org/article/c1c43e80139b48f2bdb847aa34f8da63